Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1979 Apr;38(2):171–173. doi: 10.1136/ard.38.2.171

Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.

D H Lawson, D A Henry, J Lowe, P Reavey, J A Rennie, A Solomon
PMCID: PMC1000345  PMID: 443884

Abstract

Acetylator phenotype was determined in 22 patients with spontaneous systemic lupus erythematosus and the proportion of 'slow' acetylators compared with that obtained in a group of patients with rheumatoid arthritis and a group of healthy controls. 73% of the SLE group were designated 'slow' compared with 72% of the rheumatoid group and 64% of the control group. These differences were not significant.

Full text

PDF
171

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D. Drug-induced antinuclear antibodies and lupus syndromes. Drugs. 1976;12(1):69–77. doi: 10.2165/00003495-197612010-00003. [DOI] [PubMed] [Google Scholar]
  2. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
  4. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  5. Larsson R., Karlsson E., Molin L. Spontaneous systemic lupus erythematosus and acelylator phenotype. Acta Med Scand. 1977;201(3):223–226. doi: 10.1111/j.0954-6820.1977.tb15686.x. [DOI] [PubMed] [Google Scholar]
  6. Lunde P. K., Frislid K., Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet. 1977 May-Jun;2(3):182–197. doi: 10.2165/00003088-197702030-00003. [DOI] [PubMed] [Google Scholar]
  7. Molin L., Larsson R., Karlsson E. Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand. 1977;201(3):217–222. doi: 10.1111/j.0954-6820.1977.tb15685.x. [DOI] [PubMed] [Google Scholar]
  8. Reidenberg M. M., Martin J. H. The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos. 1974 Jan-Feb;2(1):71–73. [PubMed] [Google Scholar]
  9. Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. doi: 10.1136/bmj.3.5825.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972 May-Jun;13(3):420–425. doi: 10.1002/cpt1972133420. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES